Holy Basil (Tulsi): Traditional Use, Constituents and Evidence

My nan kept a pot of holy basil by the back door in Stirling, right alongside her lemon verbena and a rosemary that had long outgrown its pot. She called it "the sacred one" and used it the way her own mother had taught her , in teas, tucked into a handkerchief, crushed between the fingers on a hot afternoon. She never made medical claims for it. She just regarded it with a certain quiet respect that I've spent the better part of twenty years trying to understand from a phytochemical angle.

Honestly, the plant rewards that curiosity.

What is holy basil, and where does it come from?

Ocimum tenuiflorum , commonly known as holy basil or tulsi , is a short-lived perennial herb in the Lamiaceae (mint) family, native to the Indian subcontinent and widely naturalised across tropical Southeast Asia and parts of Australia. It is not the same species as the sweet basil (Ocimum basilicum) you'd find in a pesto; the flavour is sharper, more clove-forward, with a peppery edge that comes in large part from its volatile oil constituents.

In Ayurvedic tradition, tulsi has been documented for well over two thousand years. The classical text Charaka Samhita, generally placed in the early centuries CE, references the plant under the name tulasi in the context of respiratory and digestive applications. It holds a prominent place in Hindu religious practice; planted in household courtyards, offered at temples, in a way that makes separating the sacred from the medicinal genuinely complicated. Which is, I'd argue, one of the more interesting historiographical problems in plant medicine research. The ritual context probably helped preserve detailed observational records that might otherwise have been lost.

Key chemical constituents

The phytochemistry of O. tenuiflorum is well-characterised. The essential oil fraction varies by chemotype, there are at least three recognised chemotypes (eugenol-rich, methyl eugenol-rich, and morphologically distinct varieties); but the major volatile constituents identified across the literature include eugenol, methyl eugenol, β-caryophyllene, ocimene, and linalool.

If you follow our terpene content, you'll recognise several of those names. Beta-caryophyllene in particular has attracted significant attention in cannabinoid science for its activity at CB2 receptors; its presence in tulsi is a good reminder that plant-derived terpenes don't exist in neat category silos. Linalool and ocimene also appear in various cannabis chemotypes, and the shared vocabulary across phytomedicine research is genuinely useful for understanding mechanisms, though it doesn't mean the plants have equivalent effects.

Beyond the volatiles, the non-volatile fraction of tulsi includes:

• Ursolic acid, a pentacyclic triterpenoid also found in rosemary and apple skin, widely studied for its in vitro properties
• Rosmarinic acid; a polyphenolic ester also present in lemon balm and rosemary; studied for antioxidant and COX-inhibitory activity in laboratory settings
• Cirsilineol and cirsimaritin, flavonoids specific to Ocimum species
• Orientin and vicenin, C-glycosylflavones identified in aqueous extracts
• Oleanolic acid; another triterpenoid that appears across numerous Lamiaceae species

The concentration of each constituent varies significantly depending on the plant part used (leaf versus stem versus seed), the extraction method, the growing conditions, and the chemotype. This is a recurring challenge in tulsi research, and it matters when trying to compare studies.

What the research shows, and what it doesn't

There is a reasonably large body of preclinical literature, cell-line and rodent studies; examining the biological activity of tulsi constituents. In vitro work has characterised antioxidant capacity in the DPPH and ABTS assay models, anti-inflammatory effects via COX and LOX pathway modulation, and antimicrobial activity against a range of organisms. That's interesting mechanistic chemistry. But in vitro findings do not translate automatically to human outcomes, and much of the tulsi literature suffers from small sample sizes, poor standardisation of the extract used, and absence of placebo controls.

Human clinical trials are fewer and generally more limited. A 2012 review published on NCBI (Jamshidi & Cohen) identified a small number of randomised trials examining cognition and metabolic markers, noting that methodological heterogeneity made pooled conclusions unreliable. A 2017 pilot trial published in the Journal of Ayurveda and Integrative Medicine looked at fixed-dose tulsi leaf extract over eight weeks in a small adult cohort, but the sample size, under sixty participants, limits how far the findings generalise. The honest answer is: the human evidence base is suggestive but not yet definitive for most of the applications traditionally associated with the plant.

I'd flag one particular area worth watching: the adaptogen research. Tulsi is frequently classified alongside ashwagandha, rhodiola, and schisandra as an adaptogen; a term with a complicated regulatory and scientific history of its own. The adaptogen framework is interesting, but it's also a category that sometimes outpaces its evidence. The short version is: the classification is plausible given the HPA-axis mechanistic hypotheses, but clinical confirmation lags well behind the marketing.

Tulsi and the TGA: how it sits in the Australian regulatory landscape

In Australia, holy basil products are most commonly found as Listed medicines on the Australian Register of Therapeutic Goods (the ARTG). Listed medicines, those assessed for quality and safety but not independently evaluated for efficacy, may only make permitted low-level health claims from the TGA's pre-approved list. A product cannot legally claim to treat, cure, or prevent any disease or condition on an ARTG Listed entry.

Tulsi is not a scheduled substance under the Poisons Standard. It does not appear in Schedule 4 (prescription only) or Schedule 8 (controlled drug) entries, and there are no import restrictions of the kind that apply to, say, kava preparations; which face specific import quantity controls under Australian Border Force regulations for personal importation. As a dried herb, leaf powder, or encapsulated extract, tulsi sits in the complementary medicine category and is widely commercially available without restriction.

That said, the TGA's Good Manufacturing Practice requirements apply to any sponsor seeking an ARTG listing. A product that makes therapeutic claims beyond what is permitted on a Listed entry would need to seek Registered medicine status, an entirely different and far more demanding regulatory pathway requiring clinical evidence of efficacy. Most tulsi products on the Australian market do not go near that pathway.

One thing that sometimes gets overlooked: the quality of commercial tulsi preparations varies considerably. A standardised extract, where the active marker compounds are verified to a consistent level; is a different product from a simple dried herb powder of unknown chemotype and provenance. The bioavailability question is also relevant here; rosmarinic acid and ursolic acid, for instance, have very different absorption profiles, and most commercial products don't specify their extract ratio or standardisation marker, which makes comparing research to commercial products genuinely difficult.

Traditional use in context

Ayurvedic applications for tulsi are documented across the respiratory system (leaves in steam preparations), digestive complaints (infusions of fresh leaf), wound care (fresh leaf poultice), and oral hygiene (chewing fresh leaves). These applications are recorded in classical texts and in the WHO's WHO Monographs on Selected Medicinal Plants series, which provides a useful reference point for the historical and traditional-use data without making clinical efficacy claims.

The plant also carries a place in traditional Thai, Indonesian, and Sri Lankan medicine, with some variation in which plant parts are used and which preparations are preferred. This isn't just historical curiosity, it gives us clues about which constituents and extraction methods might be most relevant for further research.

Between foraging sessions in the scrub around the Adelaide Hills, I'm strictly a legal-species forager, for the record; I've been going back through a well-worn copy of John Lindley's Flora Medica (1838), which doesn't mention tulsi directly but captures the Victorian enthusiasm for systematising traditional plant knowledge that shaped a lot of early Western phytochemistry. The dissonance between the richness of traditional observational knowledge and the relatively thin clinical trial base for many of these plants is something I keep coming back to. The knowledge is old. The good RCTs are scarce. Both things are true.

What to make of it all

Tulsi is a well-characterised plant chemically, with a long and documented traditional use history across multiple South and Southeast Asian systems of medicine. The constituent-level science, particularly around eugenol, rosmarinic acid, and β-caryophyllene, gives plausible mechanistic hypotheses for the effects practitioners have observed empirically for centuries. What the literature hasn't yet delivered is the scale of rigorous human clinical trials needed to confirm those hypotheses for specific outcomes.

For anyone interested in the botanical side of this, the WHO monograph remains the most balanced starting point. For practitioners and consumers in Australia, understanding the distinction between a Listed medicine claim and a clinical efficacy claim is worth the fifteen minutes it takes to read the TGA's own guidance on the topic.

My nan's pot of tulsi is still going, transplanted into a bigger terracotta after her passing. I don't make claims for it. I just think it deserves to be understood on its own terms; as a plant with real chemistry, a serious traditional record, and an evidence base that's still catching up.

Sources

• Jamshidi N, Cohen MM. The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review of the Literature, NCBI/PMC
• WHO Monographs on Selected Medicinal Plants, Vol. 4, World Health Organization
• Listed Medicines: Guidance on Permissible Indications; Therapeutic Goods Administration (TGA)
• Cohen MM. Tulsi, Ocimum tenuiflorum: A herb for all reasons, NCBI/PMC, Journal of Ayurveda and Integrative Medicine

, Naomi Ellison, Botanical & phytomedicine writer

]]>